Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 2/20 | 0.41 |
| ▸ | CTSV | O60911 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | DNMT3A | Q9Y6K1 | 1/20 | 0.41 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27174817 | 1.00 | PSMB5 (0.44) | PSMB5ALDH1A1KDM1ALMNAPSMB8 | |
| SCHEMBL30804844 | 0.93 | KDM1A (0.49) | PSMB5KDM1AMMP2CTSVCTSL | |
| SCHEMBL27174800 | 0.93 | KDM1A (0.49) | PSMB5KDM1AMMP2CTSVCTSL | |
| SCHEMBL24627793 | 0.93 | KDM1A (0.49) | PSMB5KDM1AMMP2CTSVCTSL | |
| SCHEMBL30804857 | 0.92 | ALDH1A1 (0.45) | PSMB5ALDH1A1LMNAMMP2DNMT3A | |
| SCHEMBL24627785 | 0.92 | ALDH1A1 (0.45) | PSMB5ALDH1A1LMNAMMP2DNMT3A | |
| SCHEMBL27174820 | 0.92 | ALDH1A1 (0.45) | PSMB5ALDH1A1LMNAMMP2DNMT3A | |
| SCHEMBL24627887 | 0.91 | ALDH1A1 (0.44) | PSMB5ALDH1A1LMNAMMP2DNMT3A | |
| SCHEMBL27174799 | 0.91 | ALDH1A1 (0.44) | PSMB5ALDH1A1LMNAMMP2DNMT3A | |
| SCHEMBL30804846 | 0.90 | KDM1A (0.44) | PSMB5KDM1AMMP2CTSVCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092737-A1 | SUBSTITUTED SALICYLAMIDE COMPOUNDS AND USE THEREOF | HELIOS HUAMING BIOPHARMA CO., LTD. (CN) | 2024-03-21 | — | — | US | disclosed |
| WO-2022148457-A1 | SUBSTITUTED SALICYLAMIDE COMPOUNDS AND USE THEREOF | HELIOS HUAMING BIOPHARMA CO., LTD. (CN) | 2022-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092737-A1 | SUBSTITUTED SALICYLAMIDE COMPOUNDS AND USE THEREOF | SYMPK, SLC10A2, SLC10A1 | PSMB5 4440/4885ALDH1A1 274/4885KDM1A 3354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.